Literature DB >> 9612349

Mouse and rat plasma renin concentration and gene expression in (mRen2)27 transgenic rats.

J Bohlender1, J Ménard, O Edling, D Ganten, F C Luft.   

Abstract

The (mRen2)27 transgenic rat [TGR(mRen2)27] is said to have low plasma levels of active renin. We used a direct radioimmunoassay (RIA) for mouse submaxillary renin, as well as an indirect enzyme-kinetic assay based on the generation of angiotensin I with modification of the pH optimum, to measure rat and mouse plasma renin activity (PRA), plasma renin concentration (PRC), and plasma prorenin in TGR before and after lisinopril. The relationship between rat PRC and % rat kidney extract was steepest at pH 6.0 and flat at pH 8.5, whereas the relationship between mouse PRC and purified mouse renin was steepest at pH 8.5 and flat at pH 6.0. Mouse PRC was highly correlated with direct RIA measurements (r = 0.93). PRA before lisinopril was little influenced by pH, whereas the increase with lisinopril was greatest at pH 6.5. PRC before lisinopril was fourfold higher at pH 8.5 compared with that at pH 6.0. Lisinopril increased both PRC values but reversed the pH dependency. Prorenin was fourfold higher at pH 8.5 compared with that at pH 6.0 and decreased slightly with lisinopril. Renal renin concentration was higher at pH 6.0 than at pH 8.5. With lisinopril, renal renin concentration increased at both pH values. Mouse PRC was not changed by lisinopril. Ribonuclease protection assay showed both rat and mouse renin gene expression in the kidney, which increased with lisinopril. Thus TGR have circulating active rat and mouse renin and prorenin. The notion that TGR are a "low renin" model should be revised.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9612349     DOI: 10.1152/ajpheart.1998.274.5.H1450

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  7 in total

1.  Altered tension cost in (TG(mREN-2)27) rats overexpressing the mouse renin gene.

Authors:  Carsten Zobel; Persephone Zavidou-Saroti; Birgit Bölck; Klara Brixius; Hannes Reuter; Konrad Frank; Holger Diedrichs; Jochen Müller-Ehmsen; Wilhelm Bloch; Robert H G Schwinger
Journal:  Eur J Appl Physiol       Date:  2006-10-25       Impact factor: 3.078

2.  Combination of direct renin inhibition with angiotensin type 1 receptor blockade improves aldosterone but does not improve kidney injury in the transgenic Ren2 rat.

Authors:  Adam Whaley-Connell; Javad Habibi; Ravi Nistala; Melvin R Hayden; Lakshmi Pulakat; Catherine Sinak; Bonnie Locher; Carlos M Ferrario; James R Sowers
Journal:  Regul Pept       Date:  2012-03-29

3.  Resetting of renal tissular renin-angiotensin and bradykinin-kallikrein systems after unilateral kidney denervation in rats.

Authors:  Jürgen M Bohlender; Jürg Nussberger; Frédéric Birkhäuser; Eric Grouzmann; George N Thalmann; Hans Imboden
Journal:  Histochem Cell Biol       Date:  2017-02-20       Impact factor: 4.304

4.  Antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats is mediated by suppression of the intrarenal renin-angiotensin system.

Authors:  Sarka Varcabova; Zuzana Huskova; Herbert J Kramer; Sung Hee Hwang; Bruce D Hammock; John D Imig; Kento Kitada; Ludek Cervenka
Journal:  Clin Exp Pharmacol Physiol       Date:  2013-04       Impact factor: 2.557

5.  Comparative effect of direct renin inhibition and AT1R blockade on glomerular filtration barrier injury in the transgenic Ren2 rat.

Authors:  Adam Whaley-Connell; Ravi Nistala; Javad Habibi; Melvin R Hayden; Rebecca I Schneider; Megan S Johnson; Roger Tilmon; Nathan Rehmer; Carlos M Ferrario; James R Sowers
Journal:  Am J Physiol Renal Physiol       Date:  2009-12-09

6.  Chronic treatment with the G protein-coupled receptor 30 agonist G-1 decreases blood pressure in ovariectomized mRen2.Lewis rats.

Authors:  Sarah Hoffmann Lindsey; Jonathan A Cohen; K Bridget Brosnihan; Patricia E Gallagher; Mark C Chappell
Journal:  Endocrinology       Date:  2009-04-16       Impact factor: 4.736

7.  Androgen receptor independent cardiovascular action of the antiandrogen flutamide.

Authors:  Radu Iliescu; Luciana A Campos; Wolfgang-Peter Schlegel; Ingo Morano; Ovidiu Baltatu; Michael Bader
Journal:  J Mol Med (Berl)       Date:  2003-06-12       Impact factor: 4.599

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.